PE20240110A1 - Variantes de anticuerpos felinos - Google Patents
Variantes de anticuerpos felinosInfo
- Publication number
- PE20240110A1 PE20240110A1 PE2023001243A PE2023001243A PE20240110A1 PE 20240110 A1 PE20240110 A1 PE 20240110A1 PE 2023001243 A PE2023001243 A PE 2023001243A PE 2023001243 A PE2023001243 A PE 2023001243A PE 20240110 A1 PE20240110 A1 PE 20240110A1
- Authority
- PE
- Peru
- Prior art keywords
- igg
- seq
- amino acids
- constant region
- constant domain
- Prior art date
Links
- 241000282324 Felis Species 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 238000006467 substitution reaction Methods 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 abstract 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 125000003607 serino group Chemical class [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Refiere a una IgG modificada que comprende un dominio constante IgG felino con sustituciones aminoacidicas en relacion con un dominio constante IgG felino de tipo salvaje, tales como la sustitucion de serina por histidina en la posicion 434 (S434H), y por leucina en la posicion 428 (S428L). Dicha IgG es una molecula anti-TGF? con aminoacidos establecidos en SEQ ID NO: 2, comprende una region constante Fc con los dominios CH2 y CH3, una region constante de cadena pesada (VH) con aminoacidos establecidos en SEQ ID NO: 45, 55, 65, entre otros; y una region constante de cadena ligera (VL) con aminoacidos establecidos en SEQ ID NO: 47, 57, 67, entre otros. Asimismo, la presente IgG modificada tiene una mayor afinidad por FcRn que una IgG que tiene el dominio constante de IgG felina de tipo salvaje. Tambien, se reivindican una molecula de fusion e inmunoglobulina, un vector con el acido nucleico que codifica la IgG modificada, una celula aislada que comprende el vector, y metodos de fabricacion de la presente para mejorar la semivida de los felinos y otras caracteristicas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084693P | 2020-09-29 | 2020-09-29 | |
| PCT/US2021/052579 WO2022072446A1 (en) | 2020-09-29 | 2021-09-29 | Feline antibody variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240110A1 true PE20240110A1 (es) | 2024-01-22 |
Family
ID=78599139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001243A PE20240110A1 (es) | 2020-09-29 | 2021-09-29 | Variantes de anticuerpos felinos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230382986A1 (es) |
| EP (1) | EP4221744A1 (es) |
| JP (1) | JP2023542737A (es) |
| KR (1) | KR20230091914A (es) |
| CN (1) | CN116457369A (es) |
| AR (1) | AR123645A1 (es) |
| AU (1) | AU2021352395A1 (es) |
| CA (1) | CA3195049A1 (es) |
| CL (2) | CL2023000914A1 (es) |
| CO (1) | CO2023004107A2 (es) |
| EC (1) | ECSP23030307A (es) |
| IL (1) | IL301414A (es) |
| MX (1) | MX2023003694A (es) |
| PE (1) | PE20240110A1 (es) |
| TW (2) | TW202413413A (es) |
| WO (1) | WO2022072446A1 (es) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| JP2008510466A (ja) | 2004-08-19 | 2008-04-10 | ジェネンテック・インコーポレーテッド | エフェクター機能が変更しているポリペプチド変異体 |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| EP2845865A1 (en) | 2004-11-12 | 2015-03-11 | Xencor Inc. | Fc variants with altered binding to FcRn |
| EP3825329A1 (en) * | 2007-12-26 | 2021-05-26 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| RS63063B1 (sr) | 2010-08-19 | 2022-04-29 | Zoetis Belgium S A | Anti-ngf antitela i njihova upotreba |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2013184871A1 (en) | 2012-06-06 | 2013-12-12 | Zoetis Llc | Caninized anti-ngf antibodies and methods thereof |
| WO2019113123A1 (en) * | 2017-12-04 | 2019-06-13 | Precithera, Inc. | TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING |
| JP2022504868A (ja) * | 2018-10-18 | 2022-01-13 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のための、新生仔ｆｃ受容体（ｆｃｒｎ）への結合性が変化したｆｃ変異体 |
| US20220048981A1 (en) * | 2018-12-05 | 2022-02-17 | Bica Therapeutics Inc. | Modified product of fc domain of antibody |
| IL297290A (en) * | 2020-04-17 | 2022-12-01 | Zoetis Services Llc | Feline antibody variants |
-
2021
- 2021-09-29 AR ARP210102710A patent/AR123645A1/es unknown
- 2021-09-29 MX MX2023003694A patent/MX2023003694A/es unknown
- 2021-09-29 TW TW112132477A patent/TW202413413A/zh unknown
- 2021-09-29 KR KR1020237014648A patent/KR20230091914A/ko unknown
- 2021-09-29 EP EP21806456.6A patent/EP4221744A1/en active Pending
- 2021-09-29 WO PCT/US2021/052579 patent/WO2022072446A1/en active Application Filing
- 2021-09-29 JP JP2023519633A patent/JP2023542737A/ja active Pending
- 2021-09-29 CA CA3195049A patent/CA3195049A1/en active Pending
- 2021-09-29 AU AU2021352395A patent/AU2021352395A1/en active Pending
- 2021-09-29 PE PE2023001243A patent/PE20240110A1/es unknown
- 2021-09-29 CN CN202180077397.2A patent/CN116457369A/zh active Pending
- 2021-09-29 US US18/246,725 patent/US20230382986A1/en active Pending
- 2021-09-29 TW TW110136252A patent/TWI814094B/zh active
- 2021-09-29 IL IL301414A patent/IL301414A/en unknown
-
2023
- 2023-03-29 CO CONC2023/0004107A patent/CO2023004107A2/es unknown
- 2023-03-29 CL CL2023000914A patent/CL2023000914A1/es unknown
- 2023-04-25 EC ECSENADI202330307A patent/ECSP23030307A/es unknown
-
2024
- 2024-03-18 CL CL2024000789A patent/CL2024000789A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR123645A1 (es) | 2022-12-28 |
| ECSP23030307A (es) | 2023-07-31 |
| EP4221744A1 (en) | 2023-08-09 |
| WO2022072446A1 (en) | 2022-04-07 |
| CN116457369A (zh) | 2023-07-18 |
| JP2023542737A (ja) | 2023-10-11 |
| MX2023003694A (es) | 2023-04-21 |
| US20230382986A1 (en) | 2023-11-30 |
| CA3195049A1 (en) | 2022-04-07 |
| AU2021352395A1 (en) | 2023-04-27 |
| TWI814094B (zh) | 2023-09-01 |
| CL2024000789A1 (es) | 2024-07-19 |
| KR20230091914A (ko) | 2023-06-23 |
| CO2023004107A2 (es) | 2023-04-27 |
| IL301414A (en) | 2023-05-01 |
| TW202413413A (zh) | 2024-04-01 |
| TW202222830A (zh) | 2022-06-16 |
| CL2023000914A1 (es) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190514A1 (es) | Proteinas de union de tipo anticuerpo biespecificas que se unen especificamente a cd3 y cd123 | |
| PE20230348A1 (es) | Variantes de anticuerpos felinos | |
| PE20230108A1 (es) | Variantes de anticuerpos caninos | |
| Thomson et al. | A simplified method for the efficient refolding and purification of recombinant human GM-CSF | |
| AR127516A2 (es) | VARIANTES DE Fc Y MÉTODOS PARA SU PRODUCCIÓN | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| EA201690299A1 (ru) | СТАБИЛИЗАЦИЯ Fc-СОДЕРЖАЩИХ ПОЛИПЕПТИДОВ | |
| BR112015000798A2 (pt) | heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3 | |
| JP2017512063A5 (es) | ||
| PE20121530A1 (es) | Inmunoglobulinas con dominio variable dual | |
| EA201591407A1 (ru) | Антитела, содержащие химерные константные домены | |
| AR046833A1 (es) | Anticuerpos anti-interleuquina-10 | |
| JP2016526909A5 (es) | ||
| RU2012122402A (ru) | Содержащие фактор фон виллебранда (vwf) препараты и способы, наборы и применения, связанные с ними | |
| EA201691304A1 (ru) | АНТАГОНИСТЫ НЕОНАТАЛЬНЫХ Fc-РЕЦЕПТОРОВ (FcRn) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| EA200700751A1 (ru) | Способы и композиции для улучшения продуцирования рекомбинантного белка | |
| CO7170123A2 (es) | Complejo del factor viii con xten y proteína del factor von willebrand y sus usos | |
| AR097405A1 (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a cd123 y cd3 y usos de los mismos | |
| AR099288A1 (es) | Proteínas de fusión de interleucina-10 | |
| RU2013110875A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv | |
| PE20110225A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| JP2017509335A5 (es) | ||
| Yamazaki et al. | Artificial collagen gels via self‐assembly of de novo designed peptides | |
| AR080428A1 (es) | Formulaciones liquidas estabilizadas contentivas de anticuerpos | |
| AU2016261854A1 (en) | Multimeric protein purity determination |